Barzegar Behrooz Amir, Talaie Zahra, Syahir Amir
Nanobiotechnology Research Group, Department of Biochemistry, Faculty of Biotechnology and Biomolecular Science, Universiti Putra Malaysia, Serdang 43400, Malaysia.
School of Biology, Nour Danesh Institute of Higher Education, Isfahan 84156-83111, Iran.
Pharmaceutics. 2022 Aug 15;14(8):1697. doi: 10.3390/pharmaceutics14081697.
Aggressive glioblastoma (GBM) has no known treatment as a primary brain tumor. Since the cancer is so heterogeneous, an immunosuppressive tumor microenvironment (TME) exists, and the blood-brain barrier (BBB) prevents chemotherapeutic chemicals from reaching the central nervous system (CNS), therapeutic success for GBM has been restricted. Drug delivery based on nanocarriers and nanotechnology has the potential to be a handy tool in the continuing effort to combat the challenges of treating GBM. There are various new therapies being tested to extend survival time. Maximizing therapeutic effectiveness necessitates using many treatment modalities at once. In the fight against GBM, combination treatments outperform individual ones. Combination therapies may be enhanced by using nanotechnology-based delivery techniques. Nano-chemotherapy, nano-chemotherapy-radiation, nano-chemotherapy-phototherapy, and nano-chemotherapy-immunotherapy for GBM are the focus of the current review to shed light on the current status of innovative designs.
侵袭性胶质母细胞瘤（GBM）作为原发性脑肿瘤尚无已知的治疗方法。由于这种癌症具有高度异质性，存在免疫抑制性肿瘤微环境（TME），且血脑屏障（BBB）会阻止化疗药物到达中枢神经系统（CNS），因此GBM的治疗成效一直受到限制。基于纳米载体和纳米技术的药物递送有可能成为应对GBM治疗挑战的一项便捷工具。目前正在测试各种新疗法以延长生存期。要实现治疗效果最大化，就需要同时使用多种治疗方式。在对抗GBM的过程中，联合治疗比单一治疗效果更好。基于纳米技术的递送技术可能会增强联合治疗效果。本文综述聚焦于GBM的纳米化疗、纳米化疗-放疗、纳米化疗-光疗以及纳米化疗-免疫疗法，以阐明创新设计的现状。
